奥美沙坦酯药物经济学研究的系统评价  

Systematic Evaluation on Olmesartan Medoxomil Pharmacoeconomics Studies

作　　者：范振兴[1] 谢小平 

机构地区：[1]首都医科大学宣武医院心脏科,北京100053 [2]辉瑞投资有限公司,北京100010

出　　处：《中国药房》2016年第8期1017-1019,共3页China Pharmacy

摘　　要：目的：评价奥美沙坦酯在血管紧张素Ⅱ受体拮抗药（ARB）类降压药中的药物经济学特征,为临床用药提供借鉴。方法：查阅中国知网、Pub Med等中英文检索数据库,利用设定的检索策略检索2002年1月-2013年12月发表的关于奥美沙坦酯药物经济学研究的文献,进行综合比较和一致性分析。结果：经筛选后共获得4篇在不同国家开展的针对奥美沙坦酯的药物经济学研究文献,目标人群均为原发性高血压患者,研究方法为最小成本分析或成本-效果分析,研究期限为9个月~5年不等;研究结果一致性较好,均认为奥美沙坦酯治疗成本更低或成本-效果更佳。结论：现有文献肯定了奥美沙坦酯在ARB类降压药中的药物经济学优势。OBJECTIVE：To evaluate the pharmacoeconomics characteristic of olmesartan medoxomil in ARB anti-hypertension drugs,and to provide reference for clinical drug use. METHODS：The literatures on the pharmacoeconomics study of olmesartan medoxomil published from Jan. 2002 to Dec. 2013 were searched with assigned search strategy from domestic and international databases like CNKI,Pub Med,etc.,and comprehensive comparison and consistency analysis were conducted. RESULTS：4 literatures about pharmacoeconomics study of olmesartan medoxomil in different countries were screened,with essential hypertension patients as target population cost-minimization analysis or cost-effectiveness analysis as method,and 9 months-5 years as study course. The results consistency was well and showed the treatment cost of olmesartan medoxomil was usually less or better cost-effectiveness.CONCLUSIONS：Olmesartan medoxomil shows pharmacoeconomics advantage among ARBs drugs based on existed literature review.

关 键 词：奥美沙坦酯 药物经济学 系统评价 

分 类 号：R956[医药卫生—药学]